REGENERX BIOPHARMS (RGRX) Stock Price, News & Analysis
Price Move History
- Daily moves over 5%
- 8 35 sessions, October 9, 2025 to October 14, 2026
- Largest daily move
- +80400% close of November 3, 2025
- 1-year change
- -99.3% closing prices, October 9, 2025 to October 14, 2026
- 1-month change
- +0% closing prices, August 31, 2026 to October 14, 2026
Company Description
REGENERX BIOPHARMS (OTC: RGRX) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $299.0.
RGRX has declined 99.3% over the past year. The last closing price was $0.0011.
For FY2022, REGENERX BIOPHARMS reported revenue of $77K with net income of -$1.7M and diluted earnings per share of -$0.01. The company operates at a net profit margin of -2250.4%.
This page collects what Stock Titan holds for RGRX, including price data, latest news, and financial highlights.
Stock Performance
REGENERX BIOPHARMS (RGRX) closed at $0.0011 on October 14, 2026. Over the past 12 months, the price has lost 99.3%.
RGRX Metrics & Rankings
Price returns through October 14, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
REGENERX BIOPHARMS has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 7 with negative movement. Key topics include stock split, clinical trial, fda approval. View all RGRX news →
SEC Filings
Financial Highlights
REGENERX BIOPHARMS generated $77K in revenue in FY2022, operating income reached -$1.4M (-1826.4% operating margin), and net income was -$1.7M, reflecting a -2250.4% net profit margin. Diluted earnings per share stood at -$0.01. The company generated -$941K in operating cash flow. The current ratio was 0.55, measuring current assets divided by current liabilities.
Upcoming Events
RGRX Company Profile & Sector Positioning
REGENERX BIOPHARMS (RGRX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.
Investors comparing RGRX often look at related companies in the same sector, including NEXIMMUNE INC (NEXI), Eloxx Pharmaceuticals, Inc. (ELOX), EFFECTOR THERAPUTCS INC (EFTR), INNOVEREN SCIENTIFIC INC (IVRN), and GRITSTONE BIO INC (GRTSQ). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate RGRX's relative position within its industry.